GTS Securities LLC Sells 72,846 Shares of Kenvue Inc. (NYSE:KVUE)

GTS Securities LLC trimmed its stake in Kenvue Inc. (NYSE:KVUE) by 81.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,290 shares of the company’s stock after selling 72,846 shares during the quarter. GTS Securities LLC’s holdings in Kenvue were worth $348,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of KVUE. Principle Wealth Partners LLC lifted its holdings in shares of Kenvue by 3.7% in the 4th quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after purchasing an additional 500 shares in the last quarter. White Pine Capital LLC increased its stake in Kenvue by 1.0% during the 4th quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock valued at $1,165,000 after purchasing an additional 542 shares in the last quarter. Deseret Mutual Benefit Administrators raised its holdings in Kenvue by 29.0% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock worth $54,000 after buying an additional 568 shares during the last quarter. SRS Capital Advisors Inc. lifted its stake in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after buying an additional 571 shares in the last quarter. Finally, Keystone Financial Group lifted its stake in shares of Kenvue by 4.8% in the fourth quarter. Keystone Financial Group now owns 12,736 shares of the company’s stock valued at $272,000 after buying an additional 578 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Trading Down 1.6%

NYSE KVUE opened at $23.55 on Thursday. The business’s fifty day moving average is $23.25 and its 200-day moving average is $22.64. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a market capitalization of $45.19 billion, a price-to-earnings ratio of 44.43, a PEG ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a one year low of $17.67 and a one year high of $25.17.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.23 by $0.01. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The business had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. During the same quarter in the previous year, the firm posted $0.28 earnings per share. The company’s revenue for the quarter was down 3.9% on a year-over-year basis. Equities research analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.48%. Kenvue’s payout ratio is 149.09%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of analyst reports. Citigroup upped their target price on shares of Kenvue from $22.00 to $24.50 and gave the stock a “neutral” rating in a report on Friday, May 9th. Piper Sandler raised their target price on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Evercore ISI assumed coverage on Kenvue in a research report on Monday, March 24th. They set an “in-line” rating and a $25.00 target price on the stock. Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Finally, UBS Group raised their price objective on Kenvue from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Friday, May 9th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Kenvue presently has an average rating of “Hold” and a consensus price target of $25.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.